-
Innovative TCM Jiuwei cough syrup approved for marketing
2024-02-27
Recently, the Category 1.1 innovative traditional Chinese medicine (TCM) Jiuwei Zhike Koufuye (cough syrup) of Zhuohe Pharmaceutical Group Co Ltd was approved for marketing by China's National Medical Products Administration.
-
Promulgation of the Rules for the Application of Discretion in Imposing Administrative Penalties in the Supervision and Administration of Medicinal Products
2024-02-23
Recently, the Rules for the Application of Discretion in Imposing Administrative Penalties in the Supervision and Administration of Medicinal Products were issued by China NMPA, which will come into force from August 1, 2024 onwards.
-
Innovative TCM Jiuwei Cough Syrup Approved for Marketing by China NMPA
2024-02-21
Recently, the Category 1.1 innovative traditional Chinese medicine (TCM) Jiuwei Zhike Koufuye (cough syrup) of Zhuohe Pharmaceutical Group Co Ltd was approved for marketing by China NMPA.
-
China to establish organization for poliovirus containment
2024-02-21
China will establish an organization to better fulfill its commitment to global polio eradication efforts and reduce biosecurity risks, according to the National Health Commission.
-
Crovalimab Injection Approved for Marketing by China NMPA
2024-02-07
Recently, the Crovalimab Injection (trade name: 派圣凯/Piasky) of Roche Pharma (Schweiz) AG was approved for marketing by China NMPA through the priority review and approval procedures. It is indicated for use in adults and adolescents (≥12 years old) with paroxysmal nocturnal hemoglobinuria who have not received complement inhibitor therapy.
-
IFI44L Gene Methylation Detection Kit (PCR-Melting Curve Method) Approved for Marketing
2024-02-06
Recently, the application for registration of innovative product "IFI44L Gene Methylation Detection Kit (PCR-Melting Curve Method)" of ShenZhen Sciarray Biotechnology Co., Ltd. was approved by China NMPA.
